Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-predictable routine of meetings, online calls, and deadlines is upon us once again. To cope, yes, we are brewing a cup of stimulation. Our choice, for those who track this sort of thing, is ginger spice. Goes well with a slice of pumpkin challah toast and fig butter, too. Meanwhile, here are a few tidbits to get you going in case you are out of fig butter. Hope you have a smashing day and, as always, do stay in touch. We cherish your postcards. …
Robert Califf, whom President Biden picked to lead the US. Food and Drug Administration, does not have much to show for his first tenure at the agency, STAT notes. The former FDA commissioner had grand plans for modernizing the way drug makers and the FDA collect patient data, but the notion was shelved in 2017 after he left the agency. His efforts to ban flavored tobacco products were foiled by the Obama White House. Even his push to finally fix FDA hiring woes still has not been fully implemented. Former FDA officials and Califf allies at the agency are clear: He has plenty of unfinished business that he will want to tackle as soon as he is confirmed.
Having rejected a half-billion-dollar settlement offer over the opioid crisis, Washington Attorney General Bob Ferguson is going to trial against the nation’s three biggest drug distributors seeking $38 billion, but his gamble is risky, The Associated Press says. A California state judge recently issued a tentative ruling that three counties, and the city of Oakland, did not prove drug makers used deceptive marketing to boost prescribing and create a public nuisance. And the Oklahoma Supreme Court overturned a $465 million judgment against Johnson & Johnson (JNJ) in a lawsuit alleging the company fueled the opioid crisis by deceptive marketing and created a public nuisance.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
